Certain EGFR-TKIs, such as gefitinib, afatinib, and osimertinib, have been shown to directly inhibit the G469V BRAF mutant, suppressing NSCLC cell growth in vitro (154). Here, EGFR is linked to non-small cell lung carcinoma.